|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Appendix A. False Negatives and False Negative Rates (FNRs): A ReviewThe literature cites an astounding range of laboratory FNRs,
from less than 1% to 93%. In some studies, however, the reported
FNR was actually the percentage of negative smears found to be
positive or abnormal on review. In other studies, false-negative
cases were based on a review diagnosis of ACUS rather than SIL
when the initial diagnosis was negative; although the former is
often used for a laboratory's internal review, only the latter is
appropriately used for external evaluation of a laboratory. In
addition, although an accurate laboratory FNR is based on random
rescreening of a laboratory's cases, some published Pap smear
rescreening studies focused on specimens collected from patients
at high risk for developing cervical cancer or patients who were
subsequently clinically diagnosed with SIL or carcinoma. Any
reported laboratory FNR must be analyzed carefully to determine
whether the value was accurately determined (Table_2). TABLE 2. Study results on rescreening of Pap smears initially diagnosed as negative =========================================================================================================================================================================== Reference Setting No. of Pap smears Description of samples* Threshold+ Smears found to be False negative rescreened false negative rate --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Yobs et al. (16 ) 2 University- based 19,474 Consecutive smears,excluding SIL 2.0% 30% medical centers cases with original diagnosis of unsatisfactory or diagnoses associated with glandular abnormalities Allen et al. (17 ) 2 University teaching 80 Smears from patients who had SIL ACUS 7.5% 15.0% 17.5% hospital laboratories had all negative smears within Unsatisfactory 5 years of diagnosis of high- grade SIL or carcinoma Sherman & Kelly (18 ) University teaching 123 All available smears from 20 SIL ACUS 22.7% 52.7% 66.7% hospital laboratory women with >=3 negative smears Unsatisfactory preceding a diagnosis of high- grade SIL or carcinoma Nick et al. (19 ) University teaching 351 All available negative smears Unsatisfactory 70.7% hospital laboratory from 143 women within 5 years of diagnosis of high-grade SIL Gatscha et al. (20 ) University teaching 3,962 From 1 year,random sample and Not stated 0.28% hospital targeted rescreen of smears of high-risk patients 422 All available smears in the 5 ACUS 25.8% 28.7% years preceding histologically Unsatisfactory confirmed high-grade SIL or carcinoma Tabbara & Sidawy (21 ) University teaching 2,124 Random sample; rescreening was ACUS 0.2% 1.6% laboratory performed by a cytopathology fellow Slagel et al. (22 ) University laboratory 435 Consecutive smears from a high- SIL ACUS 0.7% 3.4% 9.4% 25.0% risk patient population; automation- assisted rescreening Dean (23 ) Teaching laboratory All available negative smears Unsatisfactory 18%-29% in the 5 years preceding diagnosis of high-grade SIL or carcinoma Hatem & Wilbur (24 ) 2 Teaching centers 17 Smears from patients who had SIL ACUS 64.7% 94.1% had a negative smear in the 2 years preceding a diagnosis of high-grade SIL or carcinoma Wang (25 ) Community hospital ~200 Combination of random smears SIL 3.4% laboratory and smears in the 5 years preceding a cytologic diagnosis of high-grade SIL or carcinoma 19,623 Both random samples and SIL 0.48% consecutive smears Personal communication,SE Wang Community hospital All smears from 1 year SIL <12.5% to ML Nielsen laboratory Krieger & Naryshkin (10 ) Community hospital Quarterly random sampling ACUS 0%-17% Inhorn & Shalkham (26 ) State laboratory Random sample from 1 year ACUS 0.7% 9.0%-11.7%& All smears from 1 year from a ACUS 1.5% high-risk patient population All available smears in the 5 ACUS 13.6% years preceding cytologic diagnosis of high-grade SIL or carcinoma Colgan et al. (27 ) Independent laboratory 3,477 Consecutive smears SIL ACUS 0.4% 2.4% 12.7% Krieger & Naryshkin (10 ) Independent laboratory >=1,000,000 Random sample from 15 years ACUS 0.3%-0.7%& 4%-11% Jones (28 ) 312 Laboratories 3,762 From responding laboratories SIL ACUS 10.1% 19.9% Unsatisfactory 20.4% --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- * All smears rescreened were initially diagnosed as negative. + A false-negative cytology smear is identified when positive cells are found on rescreening of a smear initially reported to be negative. For external review, a minimum diagnosis of squamous intraepithelial lesions (SIL) on rescreening serves as the threshold for identifying a false negative. For a laboratory's internal review, the threshold is often set at atypical cells of undetermined significance (ACUS). The ACUS threshold includes SIL false negatives, and the Unsatisfactory threshold includes ACUS and SIL thresholds. & Approximated study data. =========================================================================================================================================================================== Return to top. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|